Phase I trial to assess safety and pharmacokinetics of Gefitinib plus S-1 combination therapy in patients with advanced adenocarcinoma lung
Phase 1
- Conditions
- ung Cancer
- Registration Number
- JPRN-UMIN000001594
- Lead Sponsor
- Kinki University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
a
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recommended dose of Gefitinib and S-1 combination therapy
- Secondary Outcome Measures
Name Time Method